Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study

References

• Thorp ML, Johnson ES, Yang X, et al. Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. Nephrology (Carlton) 2008 [epub ahead of print]
   Google Scholar
• Kovesday CP, Trivedi BK, Kalantar-Zadeh K, et al. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 2006;69:560-4
   PubMed Web of Science ®Google Scholar
• Li S, Foley RN, Collins AJ. Anemia, hospitalisation, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 2004;65:1864-9
   PubMed Web of Science ®Google Scholar
• Levin A, Djurdjev O, Duncan J, et al. Haemoglobin at time of referral prior to dialysis predicts survival: an association of haemoglobin with long-term outcomes. Nephrol Dial Transplant 2006;21:370-7
   PubMed Web of Science ®Google Scholar
• Finkelstein FO, Story K, Firanek C, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 2009;4:33-8
   PubMed Web of Science ®Google Scholar
• Perlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis 2005;45:658-66
   PubMed Web of Science ®Google Scholar
• Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:94-111
   PubMed Web of Science ®Google Scholar
• KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471-530
   Google Scholar
• Locatelli F, Covic A, Eckardt K-U, et al. on behalf of the ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009;24:348-54
   PubMed Web of Science ®Google Scholar
• Valderrábano F, Hörl WH, Macdougall IC, et al. PRE-dialysis survey on anaemia management. Nephrol Dial Transplant 2004;18:89-100
   Web of Science ®Google Scholar
• Lacson E Jr, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Kidney Int 2003;41:111-24
   Web of Science ®Google Scholar
• Ebben JP, Gilbertson DT, Roley RN, et al. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006;1:1205-10
   PubMed Web of Science ®Google Scholar
• Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005;68:1337-43
   PubMed Web of Science ®Google Scholar
• Yang W, Israni RK, Brunelli SM, et al. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007;18:3164-70
   PubMed Web of Science ®Google Scholar
• Richardson D. Clinical factors influencing sensitivity and response to epoetin. Nephrol Dial Transplant 2002; 17(Suppl 1): 53-9
   PubMed Web of Science ®Google Scholar
• Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin beta. Clin Pharmacol Ther 1991;50:702-12
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10: 2392-5
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006;1:1211-15
   PubMed Web of Science ®Google Scholar
• de Francisco AL, Sulowicz W, Klinger M, et al.; BA16260 Study Investigators. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract 2006;60:1687-96
   PubMed Web of Science ®Google Scholar
• Provenzano R, Besarab A, Macdougall IC, et al.; BA 16528 Study Investigators. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clin Nephrol 2007;67:306-17
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Walker R, Provenzano R, et al.; ARCTOS Study Investigators. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008;3:337-47
   PubMed Web of Science ®Google Scholar
• Klinger M, Arias M, Vargemezis V, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis 2007;50:989-1000
   PubMed Web of Science ®Google Scholar
• Canaud B, Mingardi G, Bruno J, et al.; STRIATA Study Investigators. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 2008;23:3654-61
   PubMed Web of Science ®Google Scholar
• Locatelli F, Villa G, De Francisco ALM, et al.; BA16286 Study Investigators. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis. Curr Med Res Opin 2007;23:969-79
   PubMed Web of Science ®Google Scholar
• Levin NW, Fishbane S, Cañedo FV, et al.; MAXIMA Study Investigators. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007;370:1415-21
   PubMed Web of Science ®Google Scholar
• Sulowicz W, Locatelli F, Ryckelynck JP, et al.; PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007;2:637-46
   PubMed Web of Science ®Google Scholar
• Spinowitz B, Coyne DW, Lok CE, et al.; RUBRA Study Investigators.C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrology 2008;28:280-9
   PubMed Web of Science ®Google Scholar
• Institute of Medicine Committee on Identifying and Preventing Medication Errors, Board on Health Care Services. Preventing medication errors. http://www.nap.edu/catalog/11623.html (accessed April 15, 2009)
   Google Scholar